Medicure Investor Relations Material
Latest events
Q4 2024
Medicure
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Medicure Inc
Access all reports
Medicure Inc. researches develops and commercializes human therapies for the cardiovascular market in the US. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. The company also sells UCERIS rectal foam for the induction of remission in patients with mild to moderate active distal ulcerative colitis, as well as develops deforolimus injection for acute myelogenous leukemia; roxadustat for anemia in chronic kidney disease; Apadenoson that is in Phase III clinical trials to diagnose coronary artery anomalies; and MC-4232, an oral endothelial receptor antagonist that is in Phase IIb clinical trial to treat congestive heart failure.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
MPH
Country
🇨🇦 Canada